I think the point is somewhat being missed - the company is all...

I think the point is somewhat being missed - the company is all about getting the readers into GP surgeries - the first step into wider market share for their platform, not products.

LDX will be a world renowned producer of platforms and specialised testing kits in 24 months - but it needs IP orders to do so.

Having its testing readers in place PRIOR to new tests being launched (GLIA not withstanding) is a huge attraction to companies wanting to market their own tests via LDX technology.

Forget the rest - the IP and base units is where the long-term sustainable growth is at.

This is another small part of it.